N
AMLX icon

Nuveen’s Amylyx Pharmaceuticals AMLX Stock Holding History

Nuveen’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.68M Sell
264,897
-19,051
-7% -$268K ﹤0.01% 2013
2025
Q4 		$3.43M Buy
283,948
+123,529
+77% +$1.68M ﹤0.01% 2075
2025
Q3 		$2.18M Buy
160,419
+4,883
+3% +$46K ﹤0.01% 2270
2025
Q2 		$997K Buy
+155,536
New +$757K ﹤0.01% 2606
2024
Q2 		– Sell
-137,973
Closed -$392K – 3333
2024
Q1 		$392K Sell
137,973
-883,684
-86% -$11.6M ﹤0.01% 3039
2023
Q4 		$15M Buy
1,021,657
+21,306
+2% +$327K ﹤0.01% 1338
2023
Q3 		$18.3M Buy
1,000,351
+447,277
+81% +$9.46M 0.01% 1093
2023
Q2 		$11.9M Sell
553,074
-58,858
-10% -$1.59M ﹤0.01% 1393
2023
Q1 		$18M Buy
611,932
+15,878
+3% +$552K 0.01% 1113
2022
Q4 		$22M Buy
596,054
+239,367
+67% +$8.49M 0.01% 974
2022
Q3 		$6.38M Buy
356,687
+317,200
+803% +$7.91M ﹤0.01% 1752
2022
Q2 		$761K Buy
39,487
+26,257
+198% +$312K ﹤0.01% 2901
2022
Q1 		$170K Buy
+13,230
New +$299K ﹤0.01% 3215

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Nuveen's AMLX Position: Q1 2026 in Review

Nuveen reduced its Amylyx Pharmaceuticals (AMLX) stake by 6.7% in Q1 2026, selling an estimated $268K and leaving 264,897 shares worth $3.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2013.

Nuveen first reported a position in AMLX in Q1 2022 and has held it in 13 quarters since. The position peaked at $22M in Q4 2022. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Nuveen held 264,897 shares of Amylyx Pharmaceuticals worth $3.68M as of Q1 2026.
  • Nuveen sold 19,051 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $268K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2013 holding.
  • Nuveen first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 13 quarters since.
  • Nuveen's Amylyx Pharmaceuticals position peaked at $22M in Q4 2022.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.